Ambrostherapeutics
Ambros Therapeutics is a clinical-stage biotechnology company developing medicines for diseases with high unmet medical need. The company's lead investigational program targets Complex Regional Pain Syndrome Type 1 (CRPS-1), a debilitating condition lacking FDA-approved treatments. They are currently evaluating neridronate, a differentiated bisphosphonate, in a Phase 3 pivotal trial for CRPS-1 patients.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Ambros Therapeutics is a clinical-stage biotechnology company developing novel medicines for diseases with high unmet medical need. The company's lead investigational program focuses on Complex Regional Pain Syndrome Type 1 (CRPS-1), a debilitating rare metabolic bone disease. They are advancing neridronate, a differentiated bisphosphonate, through a Phase 3 pivotal trial for CRPS-1 patients lacking FDA-approved treatment options.